Navigation Links
Multinational Research Team Led by J. Craig Venter Institute's Ewen Kirkness Sequence Body Louse Genome
Date:6/21/2010

ROCKVILLE, Md., June 21 /PRNewswire-USNewswire/ -- A global research team led by scientists from the J. Craig Venter Institute (JCVI) today published a new study in the Proceedings of the National Academy of Sciences describing the sequencing and analysis of the body louse genome. Lead author, Ewen Kirkness, Ph.D., JCVI, directed the sequencing and gene-finding efforts in the project. Detailed analysis of the genome was then conducted by a large international group of 71 scientists, coordinated by Barry Pittendrigh, University of Illinois, and Professor Evgeny Zdobnov, University of Geneva Medical School. Comparative studies of the body louse genome with other sequenced species revealed features that will enhance our understanding of the relationships between disease-vector insects, the pathogens they transmit, and the affected human hosts.

The human body louse, Pediculus humanus humanus, is a human parasite and is responsible for the transmission of bacteria that cause epidemic typhus, relapsing fever and trench fever. The team at the JCVI focused on the DNA sequencing, genome assembly and identification of genes. In addition to the targeted louse genome, the project unexpectedly yielded the complete genome sequence of a bacterial species, Riesia, that lives in close association with lice, and which is essential for survival of the insects. This study revealed that, despite having the smallest known insect genome (108 Mb) and a parasitic lifestyle, the body louse has retained a remarkably complete repertoire of 10,773 protein-coding genes. The compactness of the louse genome helped to predict the encoded genes accurately. The researchers believe that the genome will be a valuable reference for evolutionary studies of insect species, especially in the areas related to insect growth and development.

The body louse usually lives in clothing, with infestations associated with unwashed clothes for prolonged time. Infestations of body lice and the closely related head lice can cause a range of problems in humans from mild irritations to serious disease. The body louse can carry harmful bacteria, such as Rickettsia prowazekii that causes epidemic typhus, and is classified as a category B bioterrorism agent. Body and head lice are also becoming increasingly resistant to traditional pesticides so the sequencing of the body louse genome will help in the important search for new control methods facilitated by detailed molecular studies. Having the complete genome of the bacteria, Riesia, that lives within lice and provide the lice with essential nutrients such as vitamin B5, provides additional potential targets for lice eradication.

According to lead author Dr. Kirkness, "With the genome sequences of the human host, the body louse parasite, and the Riesia endosymbiont now in hand, researchers have the opportunity to gain greater insights into the co-evolution of a host-parasite-symbiont trio with the potential outcome being eradication of the body louse."

About the J. Craig Venter Institute

The JCVI is a not-for-profit research institute in Rockville, MD and La Jolla, CA dedicated to the advancement of the science of genomics; the understanding of its implications for society; and communication of those results to the scientific community, the public, and policymakers. Founded by J. Craig Venter, Ph.D., the JCVI is home to approximately 400 scientists and staff with expertise in human and evolutionary biology, genetics, bioinformatics/informatics, information technology, high-throughput DNA sequencing, genomic and environmental policy research, and public education in science and science policy. The legacy organizations of the JCVI are: The Institute for Genomic Research (TIGR), The Center for the Advancement of Genomics (TCAG), the Institute for Biological Energy Alternatives (IBEA), the Joint Technology Center (JTC), and the J. Craig Venter Science Foundation. The JCVI is a 501 (c) (3) organization. For additional information, please visit http://www.JCVI.org.


'/>"/>
SOURCE J. Craig Venter Institute
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM)
2. Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack
3. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
4. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
5. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
6. University of Minnesota researchers clear major hurdle in road to high-efficiency solar cells
7. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
8. Very Small Embryonic-Like Stem Cell Mobilization Data Presented at International Society for Stem Cell Research Annual Meeting
9. Transdel Pharmaceuticals Enters into License Agreement with Jan Marini Skin Research for Cosmeceutical Product
10. Researchers develop ultra-simple method for creating nanoscale gold coatings
11. Cellectis bioresearch Establishes The Genome Customization Award (TGCA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... February 27, 2017 A Europe-wide survey of ... researchers using animals in their research treat them with due care. ... and detailed analysis of the results indicates that there is a ... to put into practice the principles of the 3Rs (Refine, ... What ...
(Date:2/27/2017)... Feb. 27, 2017 AcelRx Pharmaceuticals, Inc. ... the development and commercialization of innovative therapies for ... the U.S. Food and Drug Administration (FDA) has ... section 505(b)(2) for DSUVIA™ (formerly ARX-04) (sufentanil sublingual ... with moderate-to-severe acute pain in a medically supervised ...
(Date:2/27/2017)... and HAMILTON, Bermuda ... (NASDAQ: ADXS ) and ... companies focused on developing cancer immunotherapies, today announced ... develop a novel cancer immunotherapy agent using Advaxis, ... SELLAS, patented WT1 targeted heteroclitic peptide antigen mixture ...
(Date:2/27/2017)... ... February 27, 2017 , ... In starting a program to hire ... grandfather, “Hire for attitude. Train for skill.” , In keeping with this philosophy, the ... as a salesman. Zamzow is hoping to replicate the practice throughout the company. , ...
Breaking Biology Technology:
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
Breaking Biology News(10 mins):